All News

EULAR flags

Digital Platforms and AI

2026 EULAR Press Release

EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.

Read Article
EULAR flags

Understanding Comorbidities in RMD

2026 EULAR Press Release

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.

Read Article
GLP-1.pink

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?

Nelly Ziade

Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.

Read Article
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026 Presence on leucocytes- change from pro inflammatory to anti inflammatory casade Also in fibroblasts in rheumatoid arthritis. Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv

Links:

Bella Mehta bella_mehta ( View Tweet)
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow Summary below. https://t.co/QC0Li38eh6

Links:

Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rheumatology Shortage Cliff in Australia & USA Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR
Dr. John Cush RheumNow ( View Tweet)
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

And we are on! A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos @RheumNow https://t.co/zTQUFcjXBI

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
It’s that time of year again! 🎉 Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London! @bella_mehta @JihaRheum @AurelieRheumo @Janetbirdope @Nellziade @RHEUMarampa @synovialjoints @Yuz6Yusof https://t.co/WvhpYJJNUk

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA? COPECARE (n=25, 1yr): sCT matches ldCT with no radiation #OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Is #axSpA overdiagnosed locally? IMPROVE-axSpA prosp study (n=969): Yes! Only 54% locally confirmed centrally #OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn

Links:

Dr. John Cush RheumNow ( View Tweet)
Interesting pilot study using line-field confocal OCT for CLE The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil) AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV

Links:

sheila RHEUMarampa ( View Tweet)
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
❎HIGH Type 1 #interferon = Worse #scleroderma In both #limited #lcSSc & #diffuse #dcSSc Leeds cohort ?biomarker #EULAR2026 @RheumNow ABST#POS1092 ABST#POS0395 https://t.co/cRrBIpLgP9

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×